NICE TA875 specifies that NHS access to semaglutide for weight management is restricted to specialist weight management services (tier 3 or 4) for patients meeting specific criteria
They must be at least 18 years of age and meet one of the following clinical criteria: Body mass index (BMI) greater than or equal to 35 when initiating GLP-1 therapy, BMI greater than or equal to 30 when initiating therapy and a diagnosis of one or more of the following: heart failure with preserved ejection fraction, uncontrolled hypertension (defined as systolic blood pressure above 140 mm Hg or diastolic blood pressure above 99 mm Hg, despite concurrent treatment with two antihypertensive medications), or chronic kidney disease stage 3a or above, BMI greater than or equal to 27 when initiating therapy with a diagnosis of one or more of the following: prediabetes (as defined by the American Diabetes Association), previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease

By pairing a GLP-1 (which reduces overall mass) with Sermorelin (which signals the body to preserve muscle and burn fat), the theoretical outcome is a dramatic improvement in body compositiona greater percentage of fat loss relative to muscle loss
Rybelsus 7mg is used to improve blood sugar control in adults with type 2 diabetes alongside diet and exercise
Read below for more information and to learn about all the amazing Needle-Free Oral Dissolving Sublingual Peptide Strips we have to offer